EXEL catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
Windows longer than 90 days are part of TrialScanner, so this list covers the next 90 days.
November 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Nov 23, 2026Sponsor estimate | NCT06545331Study of XB010 in Subjects With Solid TumorsExelixis · Locally Advanced or Metastatic Solid Tumors | EXELLead | Phase 1 | Recruiting | Locked | Locked | Locked |
- Primary completion Nov 23, 2026Sponsor estimatePhase 1NCT06545331Study of XB010 in Subjects With Solid TumorsExelixis · Locally Advanced or Metastatic Solid TumorsRecruitingEXELLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
- Primary completion Dec 2026Sponsor estimatePhase 2NCT05263050Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine TumorsFox Chase Cancer Center · Metastatic Renal Cell CarcinomaRecruitingEXELCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT05425004Cabozantinib for Patients With Recurrent or Progressive MeningiomaBaptist Health South Florida · MeningiomaRecruitingEXELCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT05613894Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant...University of Utah · Metastatic Castration-resistant Prostate CancerRecruitingEXELCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT06568562XL092 in Patients With Metastatic Castration-Resistant Prostate CancerUniversity of Utah · Metastatic Castration-resistant Prostate CancerRecruitingEXELCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2026Sponsor estimatePhase 3NCT05678673Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell CarcinomaExelixis · Non-Clear Cell Renal Cell CarcinomaActive, not recruitingEXELLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 20, 2026Sponsor estimatePhase 2NCT04413123Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCCBradley A. McGregor, MD · Papillary Renal Cell CarcinomaActive, not recruitingBMYCollaboratorEXELCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT04919122Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell CarcinomaDuke University · Metastatic Renal Cell CarcinomaActive, not recruitingEXELCollaboratorBMYCollaboratorPFECollaboratorMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 2NCT06698250Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)Anwaar Saeed · Hepatocellular CarcinomaRecruitingEXELCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 31, 2027Sponsor estimate | NCT04472767Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular CarcinomaUniversity of California, Irvine · Hepatocellular Carcinoma | EXELCollaborator | Phase 2 | Recruiting | Locked | Locked | Locked |
| Jan 31, 2027Sponsor estimate | NCT05176483Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsExelixis · Renal Cell Carcinoma (RCC) | EXELLead | Phase 1 | Recruiting | Locked | Locked | Locked |
- Primary completion Jan 31, 2027Sponsor estimatePhase 2NCT04472767Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular CarcinomaUniversity of California, Irvine · Hepatocellular CarcinomaRecruitingEXELCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2027Sponsor estimatePhase 1NCT05176483Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsExelixis · Renal Cell Carcinoma (RCC)RecruitingEXELLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Feb 1, 2027Sponsor estimate | NCT04551430Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue SarcomaWashington University School of Medicine · Metastatic Soft-tissue Sarcoma | BMYCollaboratorEXELCollaborator | Phase 2 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Feb 1, 2027Sponsor estimatePhase 2NCT04551430Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue SarcomaWashington University School of Medicine · Metastatic Soft-tissue SarcomaActive, not recruitingBMYCollaboratorEXELCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 12 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.